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Comparison of Sample Preparation Methods, Instrumentation
Platforms, and Contemporary Commercial Databases for
Identification of Clinically Relevant Mycobacteria by Matrix-Assisted
Laser Desorption Ionization–Time of Flight Mass Spectrometry
Craig B. Wilen,a Allison R. McMullen,a Carey-Ann D. Burnham a,b
Department of Pathology & Immunologya and Department of Pediatrics,b Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
Whenmycobacteria are recovered in clinical specimens, timely species-level identification is required to establish the clinical
significance of the isolate and facilitate optimization of antimicrobial therapy. Matrix-assisted laser desorption ionization–time
of flight mass spectrometry (MALDI-TOFMS) has recently been reported to be a reliable and expedited method for identifica-
tion of mycobacteria, although various specimen preparation techniques and databases for analysis are reported across studies.
Here we compared twoMALDI-TOFMS instrumentation platforms and three databases: Bruker Biotyper Real Time Classifica-
tion 3.1 (Biotyper), VitekMS Plus Saramis Premium (Saramis), and VitekMS v3.0. We evaluated two sample preparation tech-
niques and demonstrate that extractionmethods are not interchangeable across different platforms or databases. Once testing
parameters were established, a panel of 157 mycobacterial isolates (including 16Mycobacterium tuberculosis isolates) was evalu-
ated, demonstrating that with the appropriate specimen preparation, all three methods provide reliable identification for most
species. Using a score cutoff value of>1.8, the Biotyper correctly identified 133 (84.7%) isolates with nomisidentifications. Us-
ing a confidence value of>90%, Saramis correctly identified 134 (85.4%) isolates with one misidentification and VitekMS v3.0
correctly identified 140 (89.2%) isolates with one misidentification. The levels of accuracy were not significantly different across
the three platforms (P 0.14). In addition, we show that VitekMS v3.0 requires modestly fewer repeat analyses than the Bio-
typer and Saramis methods (P 0.04), which may have implications for laboratory workflow.
The genus Mycobacterium has undergone tremendous taxo-nomic revision in recent decades. There are currently 170 rec-
ognized species (http://www.bacterio.net/mycobacterium.html;
accessed 20 February 2014) with a wide range of pathogenic po-
tential from benign environmental contaminants to the patho-
genic Mycobacterium tuberculosis complex, which was estimated
to be responsible for 9 million cases of disease and 1.5 million
deaths worldwide in 2013 (1). While M. tuberculosis remains the
most clinically significant species and public health threat within
this genus, many non-tuberculosis mycobacteria (NTM) are well-
established pathogens andmay be increasing in prevalence in part
due to increased numbers of immunocompromised individuals as
well as to the increasing prevalence of medical hardware and in-
dwelling devices (2).
Whenmycobacteria are recovered from clinical specimens, es-
tablishment of a species- or complex-level identification is critical
to distinguish pathogenic species from common environmental
contaminants (such asMycobacterium gordonae) and to guide an-
timicrobial therapy, when indicated. Species-level identification
has classically relied on a variety of characteristics and methodol-
ogies, including growth rate, pigmentation, enzymatic properties
(3, 4), and high-performance liquid chromatography (HPLC),
which generates species- or complex-specificmycolic acid profiles
(5). In addition, molecular assays, including those using nucleic
acid probes, have been used for identification of some common
Mycobacterium spp., includingM. tuberculosis andMycobacterium
avium complex (6). DNA sequencing of 16S rRNA, rpoB, and
hsp65 genes is widely considered the gold standard for identifica-
tion (7). However, these methods can be time-consuming and
expensive, can require specific equipment and expertise, and often
have limited availability outside reference laboratories.
Recently, matrix-assisted laser desorption ionization–time of
flightmass spectrometry (MALDI-TOFMS) has been used to pro-
vide relatively rapid, inexpensive, and accurate identification of a
variety of microorganisms, includingMycobacterium spp. (8–11).
However, unlikemost bacteria, which can be directly spotted onto
aMALDI-TOF target plate,mycobacteria require inactivation and
extraction steps prior to analysis, both for biosafety and for access
to proteins in the cells. The inactivation step is commonly per-
formed with heat-killing and/or ethanol (8). For optimal results,
the mycobacterial protein must be extracted from the cells, most
commonly by silica bead beating, given the poorly permeable and
mycolic acid-rich cell wall. Each of these steps and protocols, in
addition to the breadth and depth of the MALDI-TOF MS refer-
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ence databases, may introduce assay variability and influence the
analytical performance characteristics of the method.
There are two commercially available MALDI-TOF MS plat-
forms: the Bruker Biotyper (Bruker, Billerica, MA) and the bio-
MérieuxVitekMS (bioMérieux, Durham,NC). Our objective was
to compare the contemporary databases and specimen prepara-
tion methods recommended for the Bruker Biotyper to those rec-
ommended for the Vitek MS. We compared solid-medium types
for organism cultivation prior toMS analysis, extractionmethods,
and the reliability and accuracy of Mycobacterium species identi-
fication.
MATERIALS AND METHODS
Clinical isolates and identification. This was an analysis of 167 banked
isolates of Mycobacterium spp. Ten isolates were used for an initial com-
parison of medium types and extraction methods, while 157 isolates were
used to assess the analytical performance characteristics of each method.
All isolates were recovered from clinical specimens submitted to the
Barnes-Jewish Hospital microbiology laboratory between 2009 and 2014.
M. tuberculosis complex,M. avium complex,Mycobacterium kansasii, and
M. gordonae were identified by a chemiluminescent DNA probe hybrid-
ization assay (AccuProbe; Hologic, Inc., Bedford, MA). All other myco-
bacterial species were identified by the Wisconsin State Laboratory of
Hygiene or the Oklahoma State Department of Public Health by mycolic
acid profile analysis (using HPLC) and/or DNA sequencing of the 16S
rRNA and rpoB genes.
Culture conditions. Unless indicated otherwise, all isolates were cul-
tured on Middlebrook 7H10 agar (7H10; Remel, Lenexa, KS) at 35°C
without supplemental CO2.Mycobacteriummarinum andMycobacterium
haemophilum were grown at 30°C. M. haemophilum was cultured on
chocolate agar. To compare the effects of medium types, a subset of iso-
lates were cultured on both 7H10 and Löwenstein-Jensen (LJ) agar at
35°C.
Experimental design. To enable direct comparison of the Biotyper
and Vitek MS mycobacterial identification methods, all extractions were
performed for both assays from isolates grown on identical culture media
at the same time. Similar biomasses, consisting of heaping inocula on a
1-l disposable loop (Nunc, Roskilde, Denmark), were used for the two
assays.
Comparison of solid media and extraction methods. We selected a
panel of 10 commonly isolatedNTM isolates to compare the Biotyper and
VitekMSprotein extractionmethods using both 7H10 andLJ solidmedia.
This collection of isolates included four rapidly growing NTM species
(twoMycobacterium abscessus, oneMycobacterium chelonae, and oneMy-
cobacterium fortuitum) and six slowly growing NTM species (two each of
M. avium complex, M. gordonae, and M. kansasii). For this pilot study,
scores and confidence values of2.0 and90%were set as the diagnostic
thresholds for the Biotyper and Vitek MS, respectively. Extractions were
done in duplicate, with each extraction method applied once per target
plate in each of two independent experiments, resulting in 40 total results
per MALDI-TOF MS platform.
Comprehensive evaluation of diverse mycobacterial isolates. For
the comparisons among the 157 Mycobacterium spp., a single extraction
was performed and the extractedmaterial was spotted in duplicate in each
of three independent experiments. Two independent operators tested
each isolate.
Biotyper specimen preparation method. Samples were extracted ac-
cording to the Bruker MALDI Biotyper standard operating procedure
(revision 2 January 2013). Briefly, mycobacterial isolates were suspended
in 300 l H2O and then heat inactivated for 30 min in a 95°C heat block.
Samples were centrifuged, resuspended in 70% ethyl alcohol (EtOH),
washed in H2O, and then resuspended in 50 l H2O prior to incubation
for 10 min at 95°C. Samples were then washed in 100% EtOH, dried, and
then subjected to vortex mixing for 1 min with 0.5-mm-diameter glass
beads (VWR, Radnor, PA) and 20l acetonitrile. After bead beating spec-
imens horizontally by the use of a vortex adaptor, 20l of 70% formic acid
was added. Samples were then centrifuged, and 1 l of supernatant was
spotted per target. After drying, 1 l of HCCA (alpha-cyano-4-hydroxy-
cinnamic acid; Bruker) matrix solution was overlaid. Bacterial Test Stan-
dard (Bruker) was direct spotted onto each target as a calibrant and con-
trol. All targets were analyzed within 3 h of the spotting procedure.
Biotyper Real Time Classification software version 3.1 and Biotyper My-
cobacteria Library 1.0 were used for analysis. All samples were analyzed
exclusively in automatic mode. The Biotyper employs a laser frequency of
60 Hz and records mass spectra from 2,000 to 20,000 Da. Each spot was
sampled in nine different areas with 40 shots per sampling area. The re-
sulting spectra were flattened, compared to a database, and analyzed to
produce a logarithmic score of from 0 to 3.0. Per themanufacturer, scores
of 2.0 are considered reliable for species-level identification, scores of
1.7 to 1.9 are accurate for genus-level identification, and scores of1.7 are
unreliable (9).
VitekMSextractionmethod. Sampleswere extracted according to the
Mycobacteria Test protocol (bioMérieux). Briefly, a suspension of myco-
bacteria was mixed with silica beads and 70% EtOH and then mechani-
cally disrupted by vortex mixing for 10 to 15 min at 3,000 rpm (Vortex
Genie 2 [Scientific Industries] with MoBio Vortex Adaptor). After bead
beating was performed, samples were incubated for 10 min at room tem-
perature and then the supernatant was transferred to a new tube. Samples
were then pelleted, dried, and resuspended in 10 l of 70% formic acid.
The suspension was incubated for 2 to 5 min, and then 10 l acetonitrile
was added. The samples were then centrifuged, and 1 l of supernatant
was added per target spot. After the extract was dried, 1 l of Vitek MS-
CHCAMatrix (bioMérieux) was overlaid and allowed to dry completely.
An Escherichia coli reference strain (ATCC 8739) was directly spotted on
each acquisition group on each slide as a calibrant and control per man-
ufacturer protocols. All slides were run within 3 h of organism applica-
tion. All samples were run exclusively in automatic mode. Spectra were
generated on the VitekMS, and the resulting spectra were simultaneously
analyzed using both the Saramis and v3.0 software. The v3.0 spectra were
analyzed using SpectraIdentifier v2.1.0, a research and development tool.
The v3.0 software is currently under development and is not yet commer-
cially available.
The Vitek MS employs a laser frequency of 50 Hz and records mass
spectra of from 2,000 to 20,000 Da. Each spot was pulsed 100 times, and
each generated a unique mass spectrum, and the mass spectra were
summed into a single spectrum that then underwent “mass binning” (12).
This resulted in an isolate identification with a confidence value of from
0% to 99.99% for Saramis and 0% to 99.9% for v3.0. Results from low-
quality or absent spectra receive a classification of “no identification”
(12).
Discrepant resolution. If the isolate identification obtained as part of
routine testing (see the description of culture conditions and identifica-
tion above) was identical to the identification generated by all three of the
MALDI-TOF MS methods, the result was considered to be correct with-
out the need for additional testing. For any isolates where discrepancies
were observed, the isolate was identified by rpoB and/or 16S rRNA gene
sequencing for definitive identification.
Assessment of organism inactivation following specimen prepara-
tion.AM. tuberculosis control strain (ATCC 25177) was used to assess the
ability of the Biotyper and Vitek MS specimen preparation protocols to
inactivate this species. Each extractionmethodwas performed in triplicate
in each of two independent experiments. For the Bruker extraction, sam-
ples were inactivated for 30 min at 95°C followed by treatment with 70%
EtOH. After the EtOHwas decanted, the pellet was resuspended in 200l
sterile H2O and the entire volume was used to inoculate a mycobacterial
growth indicator tube (MGIT) with polymyxin B, amphotericin B, nali-
dixic acid, trimethoprim, and azlocillin (PANTA) antibiotic (BD, Frank-
lin Lakes, NJ). For theVitekMS extraction,M. tuberculosiswas inactivated
with 70% EtOH and the cell pellet was resuspended in 100 l of sterile
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H2O and was used to inoculate a MGIT tube. For both methods, M.
tuberculosis inactivation was confirmed by incubation of the MGIT for 6
weeks at 35°C in a Bactec MGIT mycobacterial detection system.
Statistical analysis. TheWilcoxonmatched-pair signed-rank test was
used to analyze the impact of the extraction method on scores. Fisher’s
exact test was used to compare the effects of the extractionmethods on the
frequencies of sampleswithout identification. To compare the numbers of
repeats needed to obtain an identification, a chi-square test comparing the
three methods with the four outcomes (identification by the first, second,
or third experiment or no identification)was performed. A chi-square test
for trend (Cochran-Armitage test for trend) was then used for pairwise
analysis. A P value of less than 0.05 was considered significant. Data were
analyzed with Prism 6 (GraphPad Software Inc., La Jolla, CA) and SPSS
Version 22 (IBM, Armonk, NY).
RESULTS
Comparison of solid media. We compared NTM identification
using isolates obtained from 7H10 and LJ solid media and the
Biotyper, Saramis, and Vitek MS v3.0 methods on a panel of 10
NTM isolates. All 10 isolates were correctly identified in at least
one of two replicates in at least one of two independent experi-
ments, while no isolates were misidentified above the given
thresholds (score of 2.0 for Biotyper and confidence value of
90% for Saramis and v3.0). Using the Biotyper, 37/40 samples
from7H10 and 33/40 fromLJ agarwere correctly identified (Table
1). Using the Saramis database, 37/40 and 31/40 were correctly
identified from 7H10 and LJ agar, respectively. Finally, using the
Vitek MS v3.0 database, 39/40 and 35/40 samples were correctly
identified from 7H10 and LJ, respectively. The differences in the
frequencies of correct identifications between 7H10 and LJ for the
Biotyper, Saramis, and v3.0 methods individually were not signif-
icantly different, but the cumulative identification rate from 7H10
(113/120; 94.2%) was significantly better than that seen with LJ
(99/120; 82.5%) overall (P 0.008).
Comparison of extraction methods. Next, we evaluated
whether the method of extraction of mycobacteria grown on
7H10 medium impacted the reliability of identification. For sam-
ples analyzed by the Biotyper, 35/40 isolates extracted with the
Vitek MS method and 36/40 extracted with the Biotyper method
yielded an identification (P 0.99). Application of the Vitek MS
extraction method resulted in Biotyper scores significantly lower
than those obtained with the same samples extracted with the
Biotyper extractionmethod (median difference, 0.16; P 0.0001)
(Fig. 1A). For samples analyzed with Saramis, there were signifi-
TABLE 1 Equivalence of 7H10 and LJ solid media
Species
No. (%) of samples tested by database and extraction method combination with score2.0 (Bruker) or90% confidence
value (Vitek) in indicated medium/no. of samples tested
Bruker and Bruker Saramis and Vitek MS v3.0 and Vitek MS
7H10 LJ 7H10 LJ 7H10 LJ
M. abscessus 4/4 3/4 4/4 4/4 4/4 4/4
M. abscessus 4/4 4/4 4/4 4/4 4/4 4/4
M. chelonae 4/4 4/4 4/4 4/4 4/4 4/4
M. avium complex 4/4 4/4 4/4 1/4 4/4 2/4
M. avium complex 2/4 4/4 3/4 4/4 3/4 4/4
M. fortuitum complex 4/4 4/4 4/4 3/4 4/4 3/4
M. gordonae 3/4 2/4 4/4 4/4 4/4 4/4
M. gordonae 4/4 4/4 4/4 3/4 4/4 3/4
M. kansasii 4/4 2/4 2/4 2/4 4/4 3/4
M. kansasii 4/4 2/4 4/4 2/4 4/4 4/4
Total 37/40 (92.5) 33/40 (82.5) 37/40 (92.5) 31/40 (78) 39/40 (97.5) 35/40 (87.5)
FIG 1 The extractionmethod impacts theMALDI-TOF quality score. TenNTM isolates were extracted in parallel with either the Vitek extractionmethod or the
Bruker extractionmethod and then analyzed. (A) The Biotyper generated higher scores for samples extractedwith the Brukermethod. (B) The Saramis generated
higher confidence values and was more likely to identify samples extracted with the Vitek method. (C) Vitek MS v3.0 was relatively insensitive to the extraction
method.
Wilen et al.
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cantly more results with an identification when extraction was
performed with the Vitek MS (32/40) procedure than with the
Biotyper method (15/40) extraction procedure (P 0.0002). Ap-
plication of the Biotyper extraction method led to less-reliable
scores for samples analyzed with the Saramis (median difference,
6.2%; P  0.031) (Fig. 1B). For samples analyzed by Vitek MS
v3.0, 35/40 spots generated an identification with the Vitek MS
extraction and 30/40 gave an identification with the Biotyper ex-
traction (P 0.25). TheVitekMS v3.0 was relatively insensitive to
the extraction method (median difference, 0.01%; P  0.024)
(Fig. 1C).
Comparison of the Biotyper, Saramis, and Vitek MS v3.0
methods for mycobacterial identification. We assessed the per-
formance of the Biotyper, Saramis, and Vitek MS v3.0 for the
identification of 157 mycobacterial isolates cultivated on 7H10
(Table 2). The isolates comprise 22 different mycobacterial com-
plexes or species, including 9 complexes or species of rapid-grow-
ingNTM(n 72), 12 complexes or species of slow-growingNTM
(n 69), and M. tuberculosis (n 16).
For the Biotyper, 2/157 (1.3%) isolates were not identified at
any score in any of the three independent extractions (Table 3).
Using a modified score threshold of1.5, 147/157 (93.6%) were
correctly identified, 3/157 (1.9%) were incorrectly identified, and
7/157 (4.5%) had a score below the threshold. At a score threshold
of1.7, 133/157 (84.7%) isolates were correctly identified, 2/157
(1.3%) isolates were incorrectly identified, and 22/157 (14.0%)
isolates were not identified above the threshold. At a score thresh-
old of1.8, 128/157 (81.5%) isolates were correctly identified, no
isolates were misidentified, and 29/157 (18.5%) isolates had a
score below the threshold. At a score threshold of 2.0, 111/157
(70.7%) isolates were correctly identified, no isolates were mis-
identified, and 46/157 (29.3%) isolates had scores below 2.0.
For the Saramis, 10/157 (6.4%) isolates were not identified at
any score in any of the three independent extractions (Table 3). At
a confidence value threshold of 80%, 139/157 (88.5%) isolates
had a correct identification, 5/157 (3.2%) had an incorrect iden-
tification, and 13/157 (8.3%) had an identification below the
threshold. At a confidence value cutoff of90%, 134/157 (85.4%)
of isolates were correctly identified, 1/157 (0.6%) was incorrectly
identified, and 22/157 (14.0%) isolates had a score below the
threshold. At a confidence value threshold of 95%, 127/157
(80.9%) isolates were correctly identified, 1/157 (0.6%)was incor-
rectly identified, and 29/157 (18.5%) isolates had a score below the
threshold.
For the Vitek MS v3.0, 10/157 (6.4%) isolates were not identi-
fied at any score in any of the three independent extractions (Table
3). At a confidence value threshold of 80%, 144/157 (91.7%)
isolates had a correct identification, 1/157 (0.6%) isolates had an
incorrect identification, and 12/157 (7.6%) isolates had an iden-
tification below the threshold. At a confidence value cutoff of
90%, 140/157 (89.2%) isolates were correctly identified, 1/157
(0.6%) isolates was incorrectly identified, and 16/157 (10.2%) iso-
lates had a score below the threshold. At a confidence value thresh-
old of 95%, 139/157 (88.5%) of isolates were correctly identified,
1/157 (0.6%) was incorrectly identified, and 17/157 (10.8%) iso-
lates had a score below the threshold. Among the three platforms,
there was trend in the frequency of isolates that did not generate
an identification after three attempts (P  0.11). In a pairwise
comparison, there was a trend toward fewer unidentified isolates
with Vitek MS v3.0 than with the Biotyper (P  0.052) and, to a
lesser extent, Saramis (P 0.39).
Of the 157 isolates, 15 had a discrepancy between the original
identification and the identification obtained on one or more of
the three MALDI-TOF MS methods. Definitive identification of
these isolates was confirmed by DNA sequencing (Table 4).
Necessity of repeat testing. Next, we compared the numbers
of independent extractions, performed on different days, required
to obtain a correct identification with score or confidence value
cutoffs of1.8,90%, and90% for the Biotyper, Saramis, and
Vitek MS v3.0 methods, respectively. For the Biotyper at a score
cutoff of1.8, 99/157 (63.1%) isolates were correctly identified to
TABLE 2 Isolates tested and classification scheme
Classification Species
Rapid growers
M. abscessus complex M. abscessus
M. bolletii
M. massiliense
M. chelonae M. chelonae







M. immunogenum M. immunogenum
M. moriokaense M. moriokaense
M. mucogenicum complex M. mucogenicum
M. phocaicum
M. neoaurum M. neoaurum
M. phlei M. phlei





M. avium complex M. avium
M. intracellulare
M. chimaera
M. gordonae M. gordonae
M. haemophilum M. haemophilum
M. kansasii M. kansasii
M. kubicae M. kubicae
M. malmoense M. malmoense
M. marinum complex M. marinum
M. shottsii
M. parascrofulaceum M. parascrofulaceum
M. scrofulaceum M. scrofulaceum
M. seoulense
M. simiae complex M. simiae
M. lentiflavum
M. szulgai M. szulgai
M. terrae complex M. terrae
M. arupense
M. nonchromogenicum
M. tuberculosis complex M. tuberculosis
M. bovis
M. vaccae M. vaccae
M. xenopi M. xenopi
Identiﬁcation of Mycobacteria by MALDI
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the complex level after a single extraction, 19/157 (12.1%) isolates
were identified after two independent extractions, 10/157 (6.4%)
were identified after three independent extractions, and 29/157
(18.5%) isolates were never correctly identified (Table 5). For the
Saramis at a confidence value cutoff of 90%, 106/157 (67.5%),
11/157 (7.0%), and 18/157 (11.5%) isolates were first correctly
identified in the first, second, and third independent experiments,
respectively, while 22/157 (14.0%) isolates were never identified.
For the Vitek MS v3.0 at a cutoff of 90%, 121/157 (77.1%),
11/157 (7.0%), and 9/157 (5.7%) of the mycobacterial isolates
were first correctly identified in the first, second, and third inde-
pendent experiments, respectively, while 16/157 (10.2%) isolates
were never correctly identified. Among the three methods, there
was a significant difference in the number of independent exper-








value (%) Vitek MS v3.0
Best
confidence
value (%) Sequencing result Target sequenced
M. terrae complex M. goodii 1.10 No ID 0 No ID 0 M. moriokaense 16S rRNA gene
M. smegmatis M. phlei 1.99 M. phlei 88.4 M. phlei 96 M. phlei 16S rRNA gene and rpoB
M. scrofulaceum M. seoulense 1.52 M. scrofulaceum 99.99 M. scrofulaceum 99.99 M. scrofulaceum 16S rRNA gene
M. mucogenicum M. chelonae 2.14 M. chelonae 99.99 M. chelonae 99.99 M. chelonae rpoB
M. smegmatis M. wolinskyi 2.14 M. goodii 96.2 M. goodii 99.99 M. smegmatis groupb 16S rRNA gene and rpoB
M. smegmatis M. wolinskyi 1.95 M. goodii 92.8 M. goodii 100 M. smegmatis groupb 16S rRNA gene and rpoB
M. chelonae M. immunogenum 1.61 M. chelonae 90 M. chelonae 99.99 M. chelonae rpoB
M. chelonae M. abscessus 1.71 M. chelonae 99.99 M. chelonae 99.99 M. chelonae rpoB
M. parascrofulaceum M. scrofulaceum 1.73 M. scrofulaceum 99.9 M. scrofulaceum 99.99 M. parascrofulaceum 16S rRNA gene and rpoB
M. mucogenicum M. arupense 1.86 M. arupense 0 M. arupense 100 M. terrae complexc 16S rRNA gene
M. marinum M. shottsii 2.14 M. marinum 99.9 M. marinum 99.99 M. marinum 16S rRNA gene
M. terrae complex M. arupense 1.51 M. fortuitum 85.8 No ID 0 M. terrae complexc 16S rRNA gene
M. vaccae M. intracellulare 1.18 No ID 0 No ID 0 M. phlei 16S rRNA gene
M. septicum M. conceptionense 1.69 No ID 0 M. fortuitum 80.5 M. septicum rpoB
M. conceptionense M. senegalense 2.13 M. fortuitum 99.89 M. fortuitum 99.99 M. conceptionense rpoB
a ID, identification.
b The M. smegmatis group includes M. smegmatis, M. goodii, and M. wolinskyi.
c The M. terrae complex includes M. terrae, M. nonchromogenicum, and M. arupense.




No. of isolates identified at indicated score or confidence value and no. of runs needed for correct ID
Bruker Biotyper 1.8 Vitek MS Saramis 90% Vitek MS v3.0 90%
No ID 1 2 3 No ID 1 2 3 No ID 1 2 3
Rapid growers
M. abscessus 19 2 10 4 3 3 13 2 1 3 12 1 3
M. chelonae 13 11 2 0 0 0 11 2 0 0 12 1 0
M. fortuitum complex 16 2 14 0 0 2 13 0 1 3 9 3 1
M. immunogenum 4 0 4 0 0 0 4 0 0 0 4 0 0
M. moriokaense 1 1 0 0 0 1 0 0 0 1 0 0 0
M. mucogenicum complex 13 3 8 1 1 0 11 1 1 1 12 0 0
M. neoaurum 1 1 0 0 0 0 1 0 0 0 0 1 0
M. phlei 2 1 0 0 1 2 0 0 0 1 0 0 1
M. smegmatis complex 3 1 1 1 0 1 1 1 0 1 2 0 0
Slow growers
M. gordonae 12 1 8 0 3 3 7 0 2 0 12 0 0
M. haemophilum 3 0 3 0 0 0 2 1 0 0 3 0 0
M. kansasii 12 0 11 0 1 0 6 2 4 0 7 4 1
M. kubicae 1 1 0 0 0 1 0 0 0 0 1 0 0
M. avium complex 13 0 7 6 0 1 11 1 0 2 9 0 2
M. marinum complex 3 0 3 0 0 0 3 0 0 0 3 0 0
M. scrofulaceum complex 1 1 0 0 0 0 0 0 1 0 1 0 0
M. simiae complex 5 1 2 1 1 2 2 1 0 2 2 0 1
M. szulgai 1 0 1 0 0 0 1 0 0 0 1 0 0
M. tuberculosis complex 16 0 13 3 0 0 15 0 1 0 16 0 0
M. terrae complex 13 2 9 2 0 6 0 0 7 2 11 0 0
M. xenopi 4 0 3 1 0 0 4 0 0 0 4 0 0
M. parascrofulaceum 1 1 0 0 0 0 1 0 0 0 0 1 0
Total 157 29 99 19 10 22 106 11 18 16 121 11 9
a ID, identification.
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iments needed for identification at the given threshold (P 
0.040). In a pairwise comparison, the Biotyper performed simi-
larly to Saramis (P  0.53) whereas the Biotyper required more
runs for identification than Vitek MS v3.0 (P  0.012). Saramis
showed a trend toward increased numbers of runs needed for
identification relative to Vitek MS v3.0 (P 0.057).
DISCUSSION
Arguably the most important role of a clinical mycobacteriology
laboratory, from both a patient care perspective and a public
health perspective, is to differentiate M. tuberculosis from NTM.
In addition, current American Thoracic Society/Infectious Dis-
eases Society of America guidelines recommend that “clinically
significant NTM isolates should be routinely identified to the spe-
cies level” (13). In this study, we compared the Biotyper, Saramis,
and Vitek MS v3.0 MALDI-TOF MS methods for the identifica-
tion of mycobacteria cultivated on solid media. We demonstrated
that all three methods provide accurate and reliable identification
to the complex and/or species level for the vast majority of myco-
bacterial clinical isolates. Importantly, all three MALDI-TOF MS
methods had 100% accuracy for the identification of the 16 M.
tuberculosis complex isolates analyzed in this study. This suggests
that MALDI-TOF MS may substitute for current M. tuberculosis
identification methods, including those using DNA probes.
MALDI-TOFMS is commonly used for routine bacterial iden-
tification in clinical laboratories.However,mycobacteria require a
protein extraction procedure for organism inactivation and opti-
mal identification. The Biotyper extraction method requires ap-
proximately 90 min for preparation of 18 samples compared to
approximately 45 min for a similar number of samples using the
Vitek MS protocol. Therefore, we assessed whether the extraction
methods were interchangeable on the respective platforms.While
deviation from each manufacturer’s recommended extraction
method did not result in misidentifications, it had a negative im-
pact on the frequency of identification and score/confidence val-
ues for the Biotyper and Saramis. The Vitek MS v3.0 platform
appeared relatively unaffected by the extraction method, at least
for the 10 isolates assessed. This emphasizes that clinical samples
should be processed using the method used to generate the refer-
ence database used for analysis (8).
Despite the reliability of all three methods to distinguish M.
tuberculosis from NTM, a small number of sporadic errors were
noted with the various MS methods. All three methods misclassi-
fied the one M. parascrofulaceum isolate as M. scrofulaceum. The
maximal score for this isolate was 1.7 on Biotyper, while Saramis
and VitekMS v3.0 both reported a maximum confidence value of
99.9%. This isolate was confirmed by 16S rRNA and rpoB gene
sequencing (14), suggesting that current MALDI-TOF MS
methodsmay have difficulty distinguishingM. scrofulaceum and
M. parascrofulaceum. Testing of additional related organisms is
needed to further characterize this observation.
TheBiotyper reproducibly identified twoM. smegmatis isolates
asM.wolinskyi.However, due to the phylogenetic relationship, all
three isolates were classified as belonging to the M. smegmatis
group in this study (15). In addition, the Biotyper reproducibly
classified one M. marinum isolate as M. shottsii, which has been
reported as a pathogen of striped bass but not as a human patho-
gen (16). M. shottsii is nonpigmented, while the isolate tested was
pigmented, as isM.marinum, suggesting the possibility of an error
in the classification of this entry in the Biotyper reference data-
base. An additional limitation of the Biotyper method was the
suboptimal scores for M. chelonae isolates, with only 2/13 identi-
fied above a score of 1.8. Lowering the score threshold of M.
chelonae would have resulted in the clinically significant misclas-
sification of two isolates as M. abscessus and M. immunogenum.
Mather et al. previously reported suboptimal identification of M.
chelonae by the Biotyper, with only 7/14 isolates correctly identi-
fied at a score threshold of 2.0 (8). The frequency of correct
identification was not affected by the length of cultivation prior to
testing (8). The extraction method and Biotyper RTC software
version were the same as those used here, while the mycobacterial
reference database differed (8). In contrast, Balada-Llasat et al.
reported correct identification of 23/24 M. chelonae isolates at a
score threshold of2.0 (9). The extractionmethod andmycobac-
terial database were the same as used here, while the Biotyper RTC
software version differed. Therefore, the discrepancies among the
three studies may have been due to different software versions,
reference databases, or isolate-specific variations or to a combina-
tion of these factors.
The Saramis method adequately identified the vast majority of
isolates, including all 13M. chelonae isolates. However, unlike the
Biotyper, the Saramis method resulted in no identification for
6/13 M. terrae isolates. Four of these M. terrae isolates were com-
pletely unidentified. One of the six isolates was identified as M.
fortuitum at a confidence value of 86%. The sixth isolate was iden-
tified as two different Gram-positive bacterial species in two inde-
pendent experiments at scores between 80% and 90%, which
would have resulted in the clinical laboratory questioning the
identification and commencing troubleshooting steps. Further-
more, at a score cutoff of 80%, Saramis misidentified an M.
fortuitum isolate and an M. simiae isolate as Streptococcus angino-
sus and Hanseniaspora guilliermondii, respectively.
Other than the misidentified M. parascrofulaceum isolate, the
Vitek MS v3.0 method did not misclassify any isolate at above a
score of 80%. In addition, while the identification of M. terrae
isolates by Vitek MS v3.0 was still suboptimal relative to the Bio-
typer method, it was improved relative to Saramis. Our panel
contained one isolate previously identified as M. mageritense
(grouped in the M. smegmatis group in this study) (17). This iso-
late was correctly identified by both Biotyper and Saramis, while
no identification was provided by Vitek MS v3.0. Testing of other
M. mageritense isolates on the Vitek MS v3.0 platform is war-
ranted. Finally, VitekMS v3.0 was the only method to identify the
single M. szulgai isolate examined in this investigation.
This study had a number of strengths. First, we evaluated a
diverse and large collection of contemporary clinical isolates, in-
cluding rare NTM, many of which have not been included in any
previously publishedMALDI-TOFMS identification studies (8, 9,
18). Second, we directly compared the performances of the Bio-
typer and Vitek MS instruments. Third, this report represents the
first description of the VitekMS v3.0 platform for identification of
Mycobacterium spp. and suggests that the VitekMS v3.0may offer
modest advantages over the Biotyper and Saramis, especially by
reducing the necessity of repeat identification attempts. Finally,
we compared commercial mycobacterial reference databases,
rather than laboratory-developed databases, which enables gener-
alizability of our findings to other clinical laboratories.
This study had several limitations. First, we assayed only iso-
lates cultivated on solid medium. Second, we did not directly
study the impact of organism age on identification. In general,
Wilen et al.
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isolates were tested at least once during both “early” and “late”
growth. We performed the Biotyper and Vitek MS extractions in
parallel, so all isolates were assayed at the same stage of growth on
both instrumentation platforms. Third, despite our using a large
panel of clinically relevant NTM isolates, rare NTM spp. had dif-
ferent levels of representation based on availability. Further work
evaluating a larger number of these rare isolates is needed to de-
finitively assess the reliability of identification byMALDIMS. And
finally, multidrug-resistant and extensively drug-resistant M. tu-
berculosis isolates were not evaluated in this study.
In summary, this study demonstrated that the Biotyper, Sara-
mis, andVitekMS v3.0 systems can all readily and reliably identify
mycobacterial species and that commonly used extraction proto-
cols are adequate for organism inactivation. Implementation of
MALDI-TOF MS in the clinical laboratory may decrease turn-
around time, labor, andmarginal cost per identification relative to
current methods.
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